Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, ...
24 Março 2021 - 9:00AM
Hamilton, Bermuda, March 24, 2021 – Auris Medical Holding Ltd.
(NASDAQ: EARS), a clinical-stage company dedicated to developing
therapeutics that address important unmet medical needs in
neurotology, rhinology and allergy and CNS disorders, today
announced that it will provide a business update and report its
financial results for the second half and full year 2020 on
Wednesday, March 31, 2021. Following the announcement, Auris
Medical's management team will host a live conference call and
webcast at 8:00 am Eastern Time (2:00 pm Central European
Time).
To participate in this conference call, dial
+1-877-870-9135 (US, toll free) or +44-2071-928-338
(international), and enter passcode 5649276. A live webcast of the
conference call can be accessed in the Investor Relations section
of the Auris Medical website at www.aurismedical.com. A replay will
be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology, rhinology and allergy and CNS
disorders. The Company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125, in Phase 2) and
for the prevention of antipsychotic-induced weight gain and
somnolence (AM-201, post Phase 1b). Through its affiliate Altamira
Medica, the Company is developing a nasal spray for protection
against airborne viruses and allergens (AM-301). In addition, Auris
Medical has two Phase 3 programs under development: Sonsuvi®
(AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101)
for acute inner ear tinnitus. The Company was founded in 2003 and
is headquartered in Hamilton, Bermuda with its main operations in
Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade
on the NASDAQ Capital Market under the symbol “EARS.”
Investor contact:
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Auris Medical Holding AG da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de